Antivirals Stocks
Biopharmaceutical firms in this sector specialize in the research and commercialization of small molecules and biologics designed to inhibit viral replication cycles across therapeutic areas like hepatitis, HIV, and emerging respiratory pathogens.
As of Oct 23, 2026, Antivirals has 16 US-listed companies worth $3.2B combined. The median member moved -1.4% over the past week; IBO led at +34.3% and LABT trailed at -46.6%.
Companies in Antivirals
- ABUS – Arbutus Biopharma Corp, $648M
- CRMD – CorMedix Inc, $576M
- AVIR – Atea Pharmaceuticals Inc, $413M
- ASMB – Assembly Biosciences Inc, $409M
- INDP – Indaptus Therapeutics Inc, $380M
- ENTA – Enanta Pharmaceuticals Inc, $352M
- SIGA – SIGA Technologies Inc, $234M
- IBO – Impact BioMedical, Inc., $34M
- ALGS – Aligos Therapeutics Inc, $33.3M
- NNVC – NanoViricides Inc, $33.2M
- COCP – Cocrystal Pharma Inc, $20.8M
- AIM – AIM ImmunoTech Inc, $6.7M
- TRAW – Traws Pharma Inc, $5.7M
- SXTP – 60 Degrees Pharmaceuticals, Inc. Common Stock, $3M
- DCOY – Decoy Therapeutics Inc., $2.8M
- LABT – Lakewood-Amedex Biotherapeutics Inc. Common Stock, $1.4M